Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - Becton Dickinson (BDX) reported revenue of $5.27 billion for the quarter ended March 2025, reflecting a 4.5% increase year-over-year, but a revenue surprise of -1.74% compared to the Zacks Consensus Estimate of $5.37 billion [1] - The earnings per share (EPS) for the quarter was $3.35, up from $3.17 in the same quarter last year, with an EPS surprise of +2.13% against the consensus estimate of $3.28 [1] Revenue Performance by Segment - BD Life Sciences - Biosciences in the United States generated $142 million, slightly below the estimated $145.02 million, with no year-over-year change [4] - BD Medical - Medication Delivery Solutions in the United States reported $687 million, compared to the estimated $703.87 million, showing a year-over-year increase of +3.8% [4] - BD Interventional - International revenues were $384 million, below the estimated $394.64 million, representing a year-over-year decline of -2.8% [4] - BD Interventional - United States revenues totaled $880 million, under the estimated $913.82 million, with a year-over-year decrease of -2% [4] - Total revenues for BD Interventional were $1.26 billion, compared to the estimated $1.31 billion, reflecting a year-over-year decline of -2.2% [4] - BD Interventional - Surgery revenues were $383 million, slightly below the estimated $393.29 million, with a year-over-year increase of +1.1% [4] - BD Interventional - Peripheral Intervention revenues were $481 million, below the estimated $499.49 million, showing a year-over-year decline of -1.6% [4] - BD Interventional - Urology and Critical Care revenues were $400 million, under the estimated $413.17 million, with a year-over-year decrease of -5.7% [4] - BD Medical - Advanced Patient Monitoring revenues were $257 million, slightly below the estimated $261.87 million [4] - Total revenues for BD Medical were $2.76 billion, compared to the estimated $2.77 billion, reflecting a year-over-year increase of +12.7% [4] - BD Medical - Medication Delivery Solutions revenues were $1.12 billion, slightly below the estimated $1.15 billion, with a year-over-year increase of +0.9% [4] - BD Life Sciences - Biosciences revenues were $352 million, below the estimated $363.86 million, representing a year-over-year decline of -6.6% [4] Stock Performance - Becton Dickinson shares have returned -8.5% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]